title: [Prophylactic systemic antibiotherapy with only ceftriaxone in neutropenic patients treated in a protected environment].
abstract: Prophylactic systemic antibiotherapy with ceftriaxone (CRO) alone was tested in aplastic patients receiving total gut decontamination and treated in protected environment. To enter the study, the patients had to be afebrile when their polymorphonuclear (PMN) count fell under 500/cumm. Seventy eight therapeutic aplasias (after allogeneic or autologous bone marrow transplant conditioning regimens or high dose chemotherapy) form the basis of this report. The median duration of aplasia was 19 D (11-93 D). Forty-three patients received during 51 aplasias one single injection of CRO per day as soon as PMN count was under 500/cumm. In 23 cases (45%) the patients remained afebrile until the end of aplasia. There were 3 Staphylococcus epidermidis bacteremias (6%), 3 bacteriologically documented fevers (6%) and 1 Cryptococcus septicemia. Twenty-nine of these aplasias were part of a randomized study between group A (prophylactic CRO) and group B (non prophylactic CRO: 27 cases). In group A, there were significantly more aplasias without fever (34.5% vs 4%), and less bacteremias (10% vs 48%). Fever appeared later in group A (mean 12.5 D vs 6 D). No death was recorded during the whole study. Thus, in protected environment, prophylactic systemic antibiotherapy could still lessen the risk of bacterial infections. The side effects and the cost of such a procedure appeared to be diminished by a monoantibiotherapy.
authors.affiliation: Service d'Hématologie Clinique, Centre Hospitalier Régional de Nantes, France.
authors.forename: J L
authors.initials: JL
authors.lastname: Harousseau
authors.forename: N
authors.initials: N
authors.lastname: Milpied
authors.forename: A E
authors.initials: AE
authors.lastname: Reynaud
authors.forename: M
authors.initials: M
authors.lastname: Derriennic
authors.forename: J H
authors.initials: JH
authors.lastname: Bourhis
authors.forename: A L
authors.initials: AL
authors.lastname: Courtieu
mesh_terms: D000293:Adolescent; D000328:Adult; D000380:Agranulocytosis / Q000150:complications*; D001424:Bacterial Infections / Q000517:prevention & control*; D002443:Ceftriaxone / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D008875:Middle Aged; D009503:Neutropenia / Q000150:complications*; D010356:Patient Isolation; D011292:Premedication
chemical_list: D002443:Ceftriaxone
vernacular_title: Antibiothérapie systémique prophylactique par ceftriaxone seule chez les patients neutropéniques traités en environnement protégé.